AFFF Lawsuit
This article provides general information for educational purposes only. It is not legal advice, does not create an attorney-client relationship, and should not be relied upon as a substitute for consultation with a qualified attorney. Laws vary by state, and individualized guidance is recommended.
AFFF litigation includes different claim tracks. This guide separates personal-injury proceedings from public-water-system settlements, explains what selected court orders establish, and shows which exposure, medical and case records to gather without promising eligibility, a filing deadline or an average payout.
Key Takeaways
The court describes AFFF MDL 2873 as pending in South Carolina; this guide reviews selected dated records, not a complete live docket.
Public-water-system settlements are not an average personal-injury payout. Identify the claimant and claims covered before using any settlement number.
Medical testing and litigation proof are different: ATSDR cautions that PFAS blood tests cannot identify the exposure source or attribute a current illness to PFAS.
Ask counsel to check current filing, disclosure and notice requirements for your case; old scheduling dates are not a universal limitation period.
Preserve exposure locations and dates, product or site records, diagnosis documents and any existing case number. Neither exposure nor participation in an MDL guarantees compensation.
Lawsuit Updates
JPML reports 15,264 pending AFFF actions
The Judicial Panel on Multidistrict Litigation's October 1, 2026 report lists 15,264 actions now pending in AFFF MDL 2873. This is a dated administrative count of actions in the MDL, not a count of individual people, proven injuries, eligible claimants or expected payments. Source
CMO 33F revises expert-motion briefing
The court issued CMO 33F adopting a revised briefing schedule for Rule 702 motions concerning thyroid-cancer and liver-cancer general-causation experts. This is an expert-evidence scheduling order, not a finding that AFFF caused any individual's illness or a compensation award. Source
CMO 26O revises Group B scheduling
The court issued CMO 26O amending the schedule for further proceedings in Group B personal-injury bellwether cases. This concerns selection and expert-discovery proposals, not a completed trial, settlement or new claimant filing deadline. Source
CMO 38 addresses duplicate personal-injury filings
The court issued CMO 38 establishing a process for counsel to address multiple personal-injury actions and representation for the same plaintiff. It calls for one remaining action; prescribed duplicate-filing dismissals are not adjudications on the merits. Source
CMO 37 addresses disclosure non-compliance
The court issued CMO 37 establishing notice, cure and motion procedures concerning personal-injury plaintiffs' non-compliance with applicable fact-sheet, profile-form and documentation requirements. The process does not automatically dismiss every claimant or decide medical causation. Source
As checked on October 12, 2026, the District of South Carolina's AFFF MDL 2873 website describes the proceeding as pending. The JPML October 1 report lists 15,264 actions now pending. That is a dated count of actions, not individual people, proven injuries, eligible claimants or expected payments.
The first useful question is which claim track you mean. Public-water-system settlements exist, but their aggregate amounts are not a personal-injury payout schedule. The records below do not establish a verified average recovery for an individual. This guide reviews selected documents, not every plaintiff's status or a complete live docket; the court's repository directs readers to ECF/PACER for official records.
Four Claim Tracks: Identify Yours Before Using a Settlement Number
Individual injury after occupational or drinking-water exposure
Start with the exposure location, dates, work or residential history, and actual diagnosis records. Ask counsel how those facts connect to a particular product, defendant and legal theory. Being a firefighter, veteran, airport worker or industrial worker is not itself a determination of eligibility. Neither nearby residence nor a diagnosis automatically establishes that AFFF caused the illness.
Treat product identification and medical causation as separate evidence questions. A site record may show foam use but not your exposure; a medical record may show a diagnosis but not its cause. Mark each point as documented, inferred or still missing so the lawyer can identify what needs investigation.
Public-water-system owner or operator
Identify the specific settlement agreement and its defined class before discussing a claim form. The DuPont administrator's FAQ describes a public-water-system class with exclusions and allocation procedures using water-source flow and PFAS concentration data. Being a customer of a water system does not, by itself, make someone a qualifying class member.
Those allocation procedures are not a cancer-payout formula. Owners and operators should ask about class membership, testing data, releases, applicable forms and the current controlling deadlines. Older FAQs and amended orders may differ; do not use a water-system deadline as an individual's injury-claim limitation period.
Private-well, property or medical-monitoring inquiry
The court's introduction describes alleged personal injury, medical-monitoring needs, property damage and economic losses. Describing those allegations does not establish that every requested remedy is available or that a household well is covered by a public-water-system settlement. Bring ownership, residence and testing records to counsel and ask which claim and jurisdiction-specific rules apply.
An existing claimant or veteran
If a case already exists, bring the case number, counsel's details and any disclosure or portal notices. Ask what remains due in that particular case before submitting another complaint or signing another representation agreement. CMO 38, issued June 3, 2026, addresses multiple personal-injury filings and representation for the same plaintiff; prescribed duplicate-filing dismissals are not merits adjudications.
VA benefits are a separate inquiry. As checked October 12, 2026, VA's PFAS page states that there are no presumptions related to military PFAS exposure. Veterans may file disability claims, which VA decides case by case. Discuss service and medical records with VA or an accredited representative; exposure alone does not guarantee an award.
What the Selected Orders Establish—and What They Do Not
The August 31, 2026 CMO 33F revised Rule 702 briefing for thyroid-cancer and liver-cancer general-causation experts. The July 30, 2026 CMO 26O revised Group B selection and expert-discovery proposal scheduling. These documents concern evidence and case management, not findings that every claimant's illness was caused by AFFF or announcements of compensation.
For an existing personal-injury case, the February 25, 2026 CMO 37 matters because it establishes notice, cure and motion procedures concerning disclosure non-compliance. It does not automatically dismiss every claimant. Ask counsel which requirements and notices apply rather than treating a procedural cure period as a deadline to begin a new lawsuit.
The August 15, 2025 CMO 35 set filing and documentation procedures and vacated the bellwether then scheduled for October 20, 2025. Its listed injury categories describe claims being pursued in that order, not a universal medical-causation finding. This historical document does not establish today's trial date or revive its old filing window.
The October 2, 2023 CMO 26A amended initial personal-injury bellwether discovery-pool selection and scheduling. It belongs in the historical record, but its selection provisions are not an award for every claimant. The Lawsuit Updates timeline separately identifies each selected event's date and type.
Reading Settlement Headlines Without Inventing an Average
On February 8, 2024, the court granted final approval of the DuPont-group public-water-system settlement. Its $1.185 billion amount concerns defined water-system claims. Separately, 3M's April 1, 2024 announcement reported March 29 final approval of its public-water-supplier settlement. These are not per-person cancer awards or proof that every individual claim has settled.
Keep three questions separate: What is the aggregate settlement amount? How is a qualifying class member's allocation calculated? What would an individual actually receive under a particular offer after applicable deductions? Dividing a utility settlement by an MDL case count answers none of them.
For an individual claim, ask counsel what exposure and diagnosis proof, causation evidence, defenses and damages law support an estimate. Ask whether an actual offer exists and which fees, costs or liens would apply. The selected documents do not justify a guaranteed range, class-wide individual rate or payment date; they also do not establish that no private individual settlement could exist.
AFFF-Specific Record Checklist
Gather what you already have; a missing record is an investigation question, not an automatic eligibility decision:
- Dated employment, training or service history and the locations where foam may have been used.
- Product identifiers, purchasing or incident records, and the source of any assertion about the foam's manufacturer.
- Residential history and water-test reports with sampling dates and locations, not merely a nearby contamination headline.
- Diagnosis, pathology and treatment records; distinguish what the records say from assumptions about cause.
- Existing complaints, case numbers, representation agreements, correspondence and portal or disclosure notices.
Keep originals and label recollections separately. Do not publish private service or medical records. Ask counsel which records are needed, who holds them, and which current filing or case-management requirements control. Seek prompt individualized advice; this guide gives no national numeric filing window.
What a PFAS Blood Result Cannot Establish
ATSDR's clinician FAQs caution that blood results do not identify the exposure source, show when or how long exposure occurred, attribute a current condition to PFAS, or predict future health outcomes. A result is not a substitute for the source, timing and diagnosis questions above. Discuss symptoms, testing benefits and limitations with a qualified clinician; this guide does not recommend a screening threshold or treatment.
This material is general legal and medical information, not legal or medical advice. Reading it creates no attorney-client relationship. Individual claim eligibility, deadlines and recovery require case-specific legal review, and health concerns should be discussed with a qualified healthcare professional.
Frequently Asked Questions
Legal References
- District of South Carolina: AFFF MDL 2873 introduction
- District of South Carolina: orders repository and docket limitations
- JPML reports 15,264 pending AFFF actions (2026-10-01)
- CMO 33F revises expert-motion briefing (2026-08-31)
- CMO 26O revises Group B scheduling (2026-07-30)
- CMO 38 addresses duplicate personal-injury filings (2026-06-03)
- CMO 37 addresses disclosure non-compliance (2026-02-25)
- CMO 35 changes filing and vetting procedures (2025-08-15)
- 3M announces public-water-system settlement approval (2024-04-01)
- DuPont public-water-system settlement approved (2024-02-08)
- CMO 26A revises initial personal-injury bellwether selection (2023-10-02)
- DuPont settlement administrator: public-water-system scope and allocation
- ATSDR: PFAS clinician FAQs and blood-test limitations
- VA: PFAS exposure and case-by-case compensation claims